Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECAP: Pirfenidone Long-Term Safety Extension in IPF
NCT00662038Phase 3Completed
- Sponsor
- Genentech
- Start
- Aug 2008
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pirfenidone in idiopathic pulmonary fibrosis (IPF), sponsored by Genentech. Primary endpoint: Percentage of Participants With Adverse Events at 7.5 years. Started Aug 2008; status: completed.
02
Drugs
pirfenidone
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT00662038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00662038.